uniQure (NASDAQ:QURE – Get Free Report) and Rani Therapeutics (NASDAQ:RANI – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, risk, earnings, valuation and institutional ownership.
Valuation & Earnings
This table compares uniQure and Rani Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| uniQure | $16.10 million | 84.30 | -$198.97 million | ($3.51) | -5.51 |
| Rani Therapeutics | $6.58 million | 10.83 | -$29.67 million | ($0.19) | -2.69 |
Rani Therapeutics has lower revenue, but higher earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Rani Therapeutics, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares uniQure and Rani Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| uniQure | -1,154.84% | -96.34% | -26.40% |
| Rani Therapeutics | -493.00% | -76.64% | -56.97% |
Insider and Institutional Ownership
78.8% of uniQure shares are owned by institutional investors. Comparatively, 30.2% of Rani Therapeutics shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 26.7% of Rani Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Volatility and Risk
uniQure has a beta of 1.14, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Rani Therapeutics has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for uniQure and Rani Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| uniQure | 1 | 3 | 11 | 1 | 2.75 |
| Rani Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
uniQure currently has a consensus price target of $55.58, suggesting a potential upside of 187.25%. Rani Therapeutics has a consensus price target of $8.33, suggesting a potential upside of 1,530.47%. Given Rani Therapeutics’ higher possible upside, analysts clearly believe Rani Therapeutics is more favorable than uniQure.
Summary
uniQure beats Rani Therapeutics on 8 of the 15 factors compared between the two stocks.
About uniQure
uniQure N.V. is a biotechnology company that develops gene therapies for serious genetic and other diseases. The company uses adeno-associated virus (AAV) vectors to deliver genetic material to patients’ cells, with research and development operations in the United States and the Netherlands. Its programs have targeted conditions including Huntington’s disease, epilepsy and hemophilia B. uniQure developed the gene therapy now known as Hemgenix for hemophilia B; it is commercialized by CSL Behring under a partnership.
About Rani Therapeutics
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company developing technology to deliver biologic medicines orally. Its RaniPill platform is designed to transport drugs such as peptides and antibodies through the digestive system and release them into the intestinal wall, with the goal of offering an alternative to injections. Founded in 2012 and based in San Jose, California, the company develops its delivery platform and evaluates it with drug candidates and potential partner medicines.
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.
